Objective: To determine the safety and pharmacokinetics of alpha-1 antitrypsin (AAT) in adults and children.
the loss of beta cell function, 2 drug-induced nephrotoxicity precludes clinical application. Other immune system interventions, 3, 4 have slowed down the tempo of beta cell destruction in subjects with recently diagnosed type 1 diabetes. These approaches have included monoclonal antibodies to CD3, a component of the T cell antigen receptor complex, 5, 6 abatacept, an inhibitor of T cell costimulatory signals, 7 and alefacept, a CD2-directed LFA-3/Fc fusion protein that targets memory and effector CD4 and CD8 cells. 8 Although type 1 diabetes is widely believed to be caused by T celldependent autoimmunity, depletion of B cells using rituximab 9 also
shows some efficacy.
Each of these interventions targeted some aspect of the adaptive immune system, and interactions between innate and adaptive immunity profoundly impact the adaptive immune response to antigen. 10 Indeed, the texture of the innate immune system in the microenvironment in which T cells recognize antigen directs differentiation and maintenance of activated T cells into distinct effector or regulatory phenotypic subsets.
11
The macrophage-rich invasive insulitis process is prominent during the pathogenesis of type 1 diabetes. 12 These data suggest that blocking pro-inflammatory innate immune responses may be efficacious in treating type 1 diabetes.
Treatment with a tumor necrosis factor (TNF)-α receptor fusion
protein, etanercept, in children with new-onset type 1 diabetes, may protect residual beta cell function. 13 Similarly, treatment with anti-TNF-α in non-obese diabetic (NOD) mice restored euglycemia and self-tolerance. 14 In contrast, blockade of interleukin-1 beta (IL-1β) effects failed to halt progression of type 1 diabetes. 15 Alpha-1 antitrypsin (AAT), a member of the serpin superfamily, is an acute phase protein produced by the liver and is present in circulating blood. 16 Inflammatory cytokines upregulate production of AAT by the liver and in a positive feedback loop, AAT, a serine protease inhibitor, blunts expression of various pro-inflammatory cytokines and activation of the nuclear factor-κB (NF-κB) pathway.
Notably, AAT therapy has been safely and effectively used in humans with AAT deficiency for over 25 years. 17 Treatment with human AAT prevents islet allograft rejection in mice with chemically induced diabetes 18 and reverses new-onset diabetes in NOD mice with restoration of self-tolerance. 19 In this study, genome-wide arrays were analyzed by a systems biology approach. The results indicated that treatment blunted disease-associated expression of important pro-inflammatory molecular hubs, including TNF-α and NF-κB. 19 Because of this remarkable result in NOD mice, and its safety record in AAT-deficient patients, the RETAIN trial was undertaken to determine the efficacy of AAT in subjects with new-onset type 1 diabetes. The purpose of this phase I study was 2fold: (1) to establish the safety of weekly intravenous infusions of AAT at 45 mg/kg/wk for the first 6 weeks and 90 mg/kg/wk for the second 6 weeks in adult and pediatric participants with new-onset type 1 diabetes and (2) to determine the pharmacokinetics (PK) of AAT in adult and pediatric participants, and develop a pharmacokinetics/ pharmacodynamics (PK/PD) model that may inform dosing regimens in future studies. The protocol and consent documents were approved by independent institutional review boards. The participants or their parents provided written informed consent, and those under age 18 provided assent. An independent data safety monitoring board held regular safety reviews.
The safety sample includes all subjects who received any study treatment. Enrolled refers to any subject who enrolled at the screening visit. One pediatric subject enrolled but withdrew consent shortly thereafter and did not receive treatment. The characteristics of the patients are summarized in Table 1 . This study is registered with ClinicalTrials.gov, number NCT01183468.
| Procedures
Patients were admitted to a clinical research center for continuous observation during the infusion period. The first infusion of AAT (Aralast NP; Baxter AG Vienna, Austria) was given at a rate of 0.08 mL/kg/min for the entire infusion. For the second infusion the starting rate was 0.08 mL/kg/min, which was increased to 0.14 mL/ kg/min, and then up to 0.2 mL/kg/min if tolerated.
| Adult cohort
The 
| Pediatric cohort
The pediatric cohort began enrolling after 6 participants in the adult cohort underwent the safety review and proceeded to the high dose. Baseline insulin use (U/day/kg)
Mean ( This cohort consisted of 8 pediatric participants, aged 8 to 15 years, who received AAT 45 mg/kg weekly for 6 weeks. One participant did not receive the fourth low-dose infusion because an elevated Ddimer level was detected, but the participant completed all other infusions. After completing the week-6 infusion, each participant underwent a minimum 3-week washout period. When at least 6 participants from the pediatric cohort had safely completed the low dose and at least 6 participants from the adult cohort had safely completed the high dose, dose escalation to 90 mg/kg/wk in the pediatric cohort proceeded for the next 6 weeks, for a total of 12 infusions.
Safety reviews were performed as outlined for the adult cohort. All of the pediatric participants were cared for by pediatric endocrinologists and received a "team care" approach.
| Clinical evaluations 2.5.1 | Hemoglobin A1c
Hemoglobin A1c (HbA1c) levels were obtained at the screening visit, and before the sixth low-dose and sixth high-dose infusions. In addition, HbA1c levels were measured at 19 and 32 weeks after the first high-dose infusion, and 52, 65, 78, 91, and 104 weeks after the first low-dose infusion.
| Insulin use
Insulin use was self-reported and recorded for 5 days leading up to each follow-up, screening, and infusion visit. In addition, usage was recorded at follow-up visits at 8, 19, and 32 weeks after the first high-dose infusion, and 52, 65, 78, 91, and 104 weeks after the first low-dose infusion.
| C-peptide
Plasma C-peptide levels (ng/mL) were assessed during 2-hour or 4- 
| Biochemical assays
Biochemical autoantibody titers were assayed at Barbara Davis Center (Aurora, CO, USA) with radioimmunobinding assays. 
| AAT pharmacokinetics
Plasma samples for total AAT analysis were collected for the first and last low-and high-dose AAT infusions taken at 30 minutes prior to infusion and at the following times post-infusion: 10 minutes, 6 hours, 24 hours, 48 hours, 72 hours, 120 hours, and 168 hours.
Plasma AAT levels were determined by ELISA in the laboratory of Baxter Innovations GmbH (Vienna, Austria). The total plasma AAT concentrations measured included both the endogenous AAT and the infused AAT.
To adjust for exogenous levels of AAT, baseline values for each subject were subtracted from the concentration levels measured at each time point prior to analysis. The predosing concentration prior to the first low-dose infusion was used as the baseline value.
Dose projections assumed a linear relationship between the change from baseline concentration levels and dose (dose proportionality). This assumption was based on historic results from the drug manufacturer and our current observations. Projections at higher doses were made using the last 90 mg/kg dose of AAT as the basis. Assuming dose proportionality, concentration levels at higher doses were calculated by multiplying the amount of increase per mg/kg by the amount of the higher dose. Geometric means and confidence limits were calculated on the sum of the resulting increase and the baseline value per subject.
3 | RESULTS
| Clinical outcomes
We screened 26 patients within 100 days from diagnosis and enrolled 16 ( Figure S1 ). Infusions of AAT were given to 8 adult and 
| C-peptide responses

| HbA1c profiles
HbA1c values over time (in study days) are plotted by subject in remained in the range 6.5% to 7.5% (48-58 mmol/mol), but 2 subjects in the adult cohort and 2 subjects in the pediatric cohort, who were in the adolescence age range showed substantial increases in HbA1c levels after 100 to 200 days, perhaps due to some combination of compliance and the insulin resistance of adolescence.
| Insulin usage
Analysis of insulin use was performed using the average use over the 5 days leading up to the visit, divided by the weight in kilograms of the subject at the visit. Insulin use profiles over time (in study days)
are plotted for each subject in Figure 1 (Panels E and F). Mean daily insulin use generally remained in the range 0.2 to 0.4 U/kg/day for both cohorts during the first 12 months, although the pediatric cohort tended to have a higher mean insulin use than the adult cohort, driven in part by 2 pediatric subjects whose insulin use drifted up to 0.8 U/kg/day at week 52. Beyond the 1-year period, there was a gradual increase in mean insulin use, which was modest in the adult cohort but greater and more variable in the pediatric cohort.
| Safety
A total of 448 adverse events (AEs) were reported during the study.
More AEs were reported in the pediatric cohort (319 events) than in the adult cohort (129 events). A smaller proportion of study drug- (Table S2) . Table S1 notes there were 11 grade 3 events (9 hypoglycemias, 1 diabetic ketoacidosis, and 1 musculoskeletal pain event) and one grade 4 event (hypoglycemia). Of these, there were 3 reported serious adverse events (SAEs) during the post-treatment phase of the study (Table S3 ). The adult subject with musculoskeletal pain was briefly hospitalized, as was the pediatric subject with diabetic ketoacidosis.
The grade 4 hypoglycemic event in an adult subject was assessed as a significant medical event but did not require emergency intervention or hospitalization. None of these events were judged to be related to study therapy. One AE consisting of a rash was reported in the adult cohort and contributed to the investigator's decision to discontinue study drug in that subject. No deaths were reported.
| Ex vivo AAT pharmacodynamic assays
AAT inhibits neutrophil superoxide production, 
| AAT pharmacokinetics
Subjects were given 6 weekly low-dose infusions of 45 mg/kg AAT and 6 weekly high-dose infusions of 90 mg/kg. There was a washout period of 4 weeks in adult subjects after the last low-dose AAT infusion prior to the first high dose infusion. In pediatric subjects, the washout period ranged from 4 to 8 weeks. To investigate the effect on plasma AAT concentrations for doses higher than 90 mg/kg, we assumed dose proportionality and that different doses of AAT decline at similar rates. Support for these assumptions is provided in Figure S4 . Dose projections are shown in Figure 3 , which displays the lower limit of the 95% confidence interval of the projected concentrations at 90, 180, and 270 mg/kg AAT, separately for each cohort. In the adult cohort (Panel E), the lower confidence limit for the 180 mg/kg AAT dose is just below 2Á5 g/L at 72 hours and just below 2.0 g/L at 120 hours.
In the pediatric cohort (Panel F), the lower confidence limit for 180 mg/kg AAT is likewise just below 2.5 g/L at 72 hours, but is Data sets are available for review at www.trialshare.com.
| CONCLUSIONS
Various AAT preparations have been used therapeutically for over 20 years without notable side effects. In the present study AAT was
given to adults and children with recently diagnosed type 1 diabetes to examine its safety and pharmacokinetics. Subjects were given weekly infusions of AAT, with 6 of these being 45 mg/kg and the next 6 being 90 mg/kg.
There was an impressive lack of grade 3 or higher adverse events and none of the 3 SAE could be related to the study drug. Of 448 adverse events (AE), the majority (38.8%) were instances of hypoglycemia, which are expected when type 1 diabetes is treated with insulin. Others have reported similar safety profiles in new-onset diabetes. In a report by Gottlieb et al, 26 12 recently diagnosed subjects were given 8 consecutive weekly infusions of 80 mg/kg of AAT (Aralast, Baxter, Inc.), which were well tolerated and the only significant adverse events were related to hyperglycemia in 7 of the 12 subjects. In another study by Rachmiel et al, 27 24 subjects with recentonset type 1 diabetes received escalating doses 40, 60, or 80 mg/kg of AAT (Glassia; Kamada Ltd. Nes Ziona, Israel) over a 28-wk period.
The drug was well tolerated, although 41 adverse events were judged to be possibly or probably related to the drug, including headache, abdominal pain, and cough.
In the present study, the C-peptide AUC values during the 2-hour MMTT remained relatively stable as a mean for the adult group for 2 years (Figure 2 ) although responses were quite heterogeneous.
In the pediatric group, the decline of the mean was sharper, and fell to very low levels in 4 of the subjects at 2 years. Note that in both groups the mean C-peptide levels remained stable during the period that AAT was being administered. While comparisons to historical data should be interpreted with caution, an analysis of Diabetes TrialNet data found that shortly after diagnosis the 2-hour C-peptide AUC levels declined at a rate of 0.0172 pmol/mL/mo (0.206 per year). 28 In our study the C-peptide AUC had a mean increase of 0.013 for adults and a mean decrease of 0.191 for pediatric subjects over the first year, both lower than 0.206. It is not surprising that Cpeptide secretion fell more rapidly in the pediatric group because function falls off more rapidly in younger subjects. 28 Because our study had no placebo control it is not possible to conclude that AAT had any beneficial effect. The studies by Gottlieb et al 26 and Rachmiel et al 27 were also not controlled, so firm conclusions about efficacy cannot be made. The possibility that there were responders or non-responders to AAT can also not be evaluated without adequate controls.
A major challenge is determining the minimal concentration of AAT required to have a meaningful anti-inflammatory effect. In the study by Gottlieb et al, 26 AAT treatment of recent-onset type 1 diabetes patients with 80 mg/kg led to a reduction of TLR4-induced cellular IL-1β in monocytes, and similar reductions were found with TLR7/8 and TLR3 agonists. Based on studies in rodents using injections of human AAT, we predicted that AAT levels increased from about 1 g/L to the range of 2 to 2.5 g/L would be sufficient to reduce pro-inflammatory responses and we predicted a dose of 90 mg/kg would accomplish this AAT concentration. Nonetheless, after infusion of 90 mg/kg, AAT levels remained above 2.0 g/L for only a few days.
To further evaluate the dose-related effects of AAT, pharmacodynamic assays were performed using fresh blood from adults with type 1 diabetes. Quantitative real-time PCR analysis revealed that AAT suppressed expression of genes involved in NF-κB activation (IKBKE, TLR1, and NOD1) and apoptosis pathways (TRADD) in all
FIGURE 2 Dose response of alpha-1 antitrypsin (AAT) on fresh blood. Data are mean AE SD from 9 adult subjects with type 1 diabetes (normalized to HK genes + no AAT). Associations between no AAT and different concentrations of AAT are tested using Paired t test and a P-value <.05 determined statistical significance. *P < .05, **P < .005 subjects tested. Importantly, ≥50% inhibition was achieved with AAT in the 2.5 to 5.0 mg/mL range. These novel findings offer new insight to the molecular mechanisms responsible for the early effects of AAT on human hematopoietic cells, and may help explain how direct effects of AAT on innate immunity could temper the adaptive response in type 1 diabetes and other inflammatory diseases. [29] [30] [31] [32] [33] [34] Inclusion of these PCR targets in future dosing studies may help determine dosing appropriate to reduce pro-inflammatory response beyond a few days.
In the NOD mouse model, both short-term treatment with TNF-α pathway blockade 14 and AAT 19 restored euglycemia and self- In conclusion, the intravenous administration of AAT to adults and children with new-onset type 1 diabetes was well tolerated and safe. However, our PK and PD studies suggest that weekly doses of more than 90 mg/kg of AAT may be required for optimal efficacy.
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